Chronic obstructive pulmonary disease (COPD) is a long-term lung condition with progressive airflow limitation that makes breathing increasingly difficult. It includes chronic bronchitis and emphysema phenotypes and is strongly linked to smoking and environmental exposures.
Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.
Altesa BioSciences reported positive Phase 2a challenge study results for vapendavir, an oral rhinovirus capsid inhibitor, showing reduced viral load and inflammation in COPD patients infected with rhinovirus. The data support vapendavir's potential to prevent rhinovirus-driven COPD exacerbations, and the company has initiated a Phase 2b CARDINAL trial to further evaluate the treatment.
FDA approves MannKind's Afrezza inhaled insulin for children aged 6+ with type 1 and type 2 diabetes. Separately, an updated label provides new starting dose guidance for adults switching from injections or insulin pumps.
Apogee Therapeutics will present Phase 2 APEX Part B data for zumilokibart on May 27, 2026. Affinity Asset Advisors increased its stake to 1.23 million shares valued at $93.21 million. The stock rose 86.9% over the past year.
FDA approves AstraZeneca's Breztri Aerosphere as the first single-inhaler triple therapy for asthma in patients aged 12+, based on Phase III KALOS and LOGOS trials showing improved lung function and reduced exacerbations versus dual therapy.
Altesa BioSciences closed an oversubscribed $75 million Series B financing led by Forbion with participation from Sanofi to advance vapendavir, a first-in-class oral antiviral targeting rhinovirus infections in COPD patients.
New real-world effectiveness data presented at RSVVW'26 demonstrate that GSK's Arexvy RSV vaccine was associated with a 75.6% reduction in RSV-related hospitalizations among adults aged 60 and older, with exploratory findings suggesting potential benefits for cardiovascular and respiratory complications.
Zydus Lifesciences received USFDA final approval for 32 mg bosentan tablets for pediatric PAH and Ammonium Lactate Cream, 12%, while launching an affordable respiratory device in India.
AstraZeneca has completed a Phase IIb heart failure trial for AZD5462, finished a real-world breast cancer study in Brazil, and is recruiting for an observational COPD study in heart clinic patients.
Savara Inc. announced the FDA has accepted its resubmitted Biologics License Application for MOLBREEVI, a treatment for autoimmune pulmonary alveolar proteinosis, with Priority Review granted and a target decision date of August 22, 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07591792 |
Outpatient Rehabilitation Programmes for Myocardial Ischemia, Heart Failure, and COPD: Satisfaction, Participation, Test Outcomes, and Factors Associated With Positive Changes in Test Results as Well as Level of Participation |
NOT_YET_RECRUITING | |
| NCT07576894 |
Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary Disease |
RECRUITING | NA |
| NCT07575841 |
Pulmonary Rehabilitation Frequency in COPD Patients |
NOT_YET_RECRUITING | NA |
| NCT07573098 |
Digital Tool for Improved Self-management of COPD |
RECRUITING | NA |
| NCT07570667 |
Global Longitudinal Health Monitoring and Blood Sample Collection Study to Promote Early-stage Disease Detection and Personalized/Precision Care Using Innovative Research Platforms |
NOT_YET_RECRUITING | |
| NCT07567872 |
A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD |
NOT_YET_RECRUITING | PHASE1 |
| NCT07566195 |
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations |
RECRUITING | PHASE3 |
| NCT07543601 |
Enhanced COPD Management in Suspected Lung Cancer Patients |
RECRUITING | NA |
| NCT07524023 |
Emotional-distress-based Integrated Care Programme in Patients With Stable COPD |
RECRUITING | NA |
| NCT07519499 |
Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 Injection |
NOT_YET_RECRUITING | PHASE2 |
